USP2a alters chemotherapeutic response by modulating redox

Cell Death and Disease

Volumn 4, Issue 9, 2013, Pages

  Benassi, B ^a   Marani, M ^b   Loda, M ^c,d   Blandino, G ^b  

^a ENEA C R CASACCIA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

c Myc; Chemotherapy; GSH; miR 34b c; Prostate cancer; USP2a

Indexed keywords

CISPLATIN; DOXORUBICIN; GLUTATHIONE; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MYC PROTEIN; REACTIVE OXYGEN METABOLITE; UBIQUITIN SPECIFIC PROTEASE 2A; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL IMMORTALIZATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DEPOLARIZATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATION REDUCTION REACTION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; UPREGULATION; WILD TYPE;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENDOPEPTIDASES; EPITHELIAL CELLS; FREE RADICAL SCAVENGERS; GLUTATHIONE; HUMANS; MALE; MICRORNAS; MODELS, BIOLOGICAL; OXIDANTS; OXIDATION-REDUCTION; PROSTATE; PROTO-ONCOGENE PROTEINS C-MYC; REACTIVE OXYGEN SPECIES;

EID: 84885000571     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.289     Document Type: Article

References (60)

1. Bernards R. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005; 123: 773-786
2. Salmena L, Pandolfi PP. Changing venues for tumour suppression: Balancing destruction and localization by monoubiquitylation. Nat Rev Cancer 2007; 7: 409-413
3. Yang Y, Kitagaki J, Wang H, Hou DX, Perantoni AO. Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci 2009; 100: 24-28
4. Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 2011; 103: 1007-1017
5. Inuzuka H, Fukushima H, Shaik S, Liu P, Lau AW, Wei W. Mcl-1 ubiquitination and destruction. Oncotarget 2011; 2: 239-244
6. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Proteotoxic stress targeted therapy (PSTT): Induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget 2011; 2: 209-221
7. Donna LD, Lagadec C, Pajonk F. Radioresistance of prostate cancer cells with low proteasome activity. Prostate 2011; 72: 868-874
8. Jandial DD, Farshchi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ, Howell SB. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res 2009; 15: 553-560
9. Liu L, Yang C, Herzog C, Seth R, Kaushal GP. Proteasome inhibitors prevent cisplatininduced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity. Biochem Pharmacol 2010; 79: 137-146
10. Stringer DK, Piper RC. Terminating protein ubiquitination: Hasta la vista, ubiquitin. Cell Cycle 2011; 10: 3067-3071
11. Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S et al. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res 2006; 66: 8625-8632
12. Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 2004; 5: 253-261
13. Stevenson LF, Sparks A, Allende-Vega N, Xirodimas DP, Lane DP, Saville MK. The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J 2007; 26: 976-986
14. Allende-Vega N, Sparks A, Lane DP, Saville MK. MdmX is a substrate for the deubiquitinating enzyme USP2a. Oncogene 2010; 29: 432-441
15. Oh KH, Yang SW, Park JM, Seol JH, Iemura S, Natsume T et al. Control of AIF-mediated cell death by antagonistic functions of CHIP ubiquitin E3 ligase and USP2 deubiquitinating enzyme. Cell Death Differ 2011; 18: 1326-1336
16. Shi Y, Solomon LR, Pereda-Lopez A, Giranda VL, Luo Y, Johnson EF et al. The deubiquitinase USP2A regulates the stability of aurora-A. J Biol Chem 2011; 286: 38960-38968
17. Shan J, Zhao W, Gu W. Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol Cell 2009; 36: 469-476
18. Liu Z, Zanata SM, Kim J, Peterson MA, Di Vizio D, Chirieac LR et al. The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation. Oncogene 2012; 32: 1660-1669
19. Benassi B, Flavin R, Marchionni L, Zanata S, Pan Y, Chowdhury D et al. MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer. Cancer Discov 2012; 2: 236-247
20. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261
21. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67: 6130-6135
22. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008; 27: 1788-1793
23. Hummel R, Hussey DJ, Haier J. MicroRNAs: Predictors and modifiers of chemo-And radiotherapy in different tumour types. Eur J Cancer 2010; 46: 298-311
24. Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A et al. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 2010; 285: 19076-19084
25. Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z et al. miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem 2011; 350: 207-213
26. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 2008; 377: 114-119
27. Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen MB. MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther 2008; 7: 1288-1296
28. Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 2010; 70: 1501-1512
29. Varbiro G, Veres B, Gallyas F Jr, Sumegi B. Direct effect of taxol on free radical formation and mitochondrial permeability transition. Free Radical Biol Med 2001; 31: 548-558
30. Ozben T. Oxidative stress and apoptosis: Impact on cancer therapy. Journal of Pharmacological Science 2007; 96: 2181-2196
31. Mediavilla-Varela M, Pacheco FJ, Almaguel F, Perez J, Sahakian E, Daniels TR et al. Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Molecular Cancer 2009; 28: 68-74
32. Shah N, Dizon DS. New-generation platinum agents for solid tumors. Future Oncol 2009; 5: 33-42
33. Itoh T, Terazawa R, Kojima K, Nakane K, Deguchi T, Ando M et al. Cisplatin induces production of reactive oxygen species via NADPH oxidase activation in human prostate cancer cells. Free Radic Res 2011; 45: 1033-1039
34. Benassi B, Fanciulli M, Fiorentino F, Porrello A, Chiorino G, Loda M et al. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell 2006; 21: 509-519
35. Schweyer S, Soruri A, Heintze A, Radzun HJ, Fayyazi A. The role of reactive oxygen species in cisplatin-induced apoptosis in human malignant testicular germ cell lines. Int J Oncol 2004; 25: 1671-1676
36. Bragado P, Armesilla A, Silva A, Porras A. Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis 2007; 12: 1733-1742
37. el-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 1997; 9: 79-87
38. Hattinger CM, Stoico G, Michelacci F, Pasello M, Scionti I, Remondini D et al. Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. Genes Chromosomes Cancer 2009; 48: 289-309
39. Benassi B, Zupi G, Biroccio A. Gamma-glutamylcysteine synthetase mediates the c-Myc-dependent response to antineoplastic agents in melanoma cells. Mol Pharm 2007; 72: 1015-1023
40. Yang Y, Li CC, Weissman AM. Regulating the p53 system through ubiquitination. Oncogene 2004; 23: 2096-2106
41. Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM. Cancer-predisposing mutations within the RING domain of BRCA1: Loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci USA 2001; 98: 5134-5139
42. Kim J, Kim WJ, Liu Z, Loda M, Freeman MR. The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle 2012; 11: 1123-1130
43. Mahul-Mellier AL, Pazarentzos E, Datler C, Iwasawa R, AbuAli G, Lin B, Grimm S. De-ubiquitinating protease USP2a targets RIP1 and TRAF2 to mediate cell death by TNF. Cell Death Differ 2012; 19: 891-899
44. Mahul-Mellier AL, Datler C, Pazarentzos E, Lin B, Chaisaklert W, Abuali G, Grimm S. De-ubiquitinating proteases USP2a and USP2c cause apoptosis by stabilising RIP1. Biochim Biophys Acta 2012; 1823: 1353-1365
45. Nicolson GL, Conklin KA. Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy. Clin Exp Metastasis 2008; 25: 161-169
46. Pieniazek A, Czepas J, Piasecka-Zelga J, Gwoździń ski K, Koceva-Chy"a A. Oxidative stress induced in rat liver by anticancer drugs doxorubicin, paclitaxel and docetaxel. Adv Med Sci 2013; 20: 24-31
47. Battisti V, Maders LD, Bagatini MD, Reetz LG, Chiesa J, Battisti IE et al. Oxidative stress and antioxidant status in prostate cancer patients: Relation to Gleason score, treatment and bone metastasis. Biomed Pharmacother 2011; 65: 516-524
48. Shiota M, Yokomizo A, Naito S. Pro-survival and anti-Apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer. Endocr Relat Cancer 2012; 19: R243-R253
49. Selvendiran K, Ahmed S, Dayton A, Ravi Y, Kuppusamy ML, Bratasz A et al. HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase. Mol Cancer Res 2010; 8: 1188-1197
50. Drayton RM. The role of microRNA in the response to cisplatin treatment. Biochem Soc Trans 2012; 40: 821-825
51. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008; 7: 1-9
52. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007; 67: 11111-11116
53. Watahiki A, Wang Y, Morris J, Dennis K, O'Dwyer HM, Gleave M et al. MicroRNAs associated with metastatic prostate cancer. PLoS One 2011; 6: E24950
54. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997; 57: 524-531
55. Iversen PL, Arora V, Acker AJ, Mason DH, Devi GR. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin Cancer Res 2003; 9: 2510-2519
56. Leonetti C, Biroccio A, D'Angelo C, Semple SC, Scarsella M, Zupi G. Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer. Prostate 2007; 67: 1475-1485
57. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458: 762-765
58. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 2008; 3: E2236
59. Sugimura K, Miyata H, Tanaka K, Hamano R, Takahashi T, Kurokawa Y et al. Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res 2012; 18: 5144-5153
60. Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 2007; 6: 5